Lyell Immunopharma, Inc.
Income Statement
| Line Item | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Sep 2020 | Jun 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.7M | $553.0K | $2.8M | $2.8M | $2.6M | $2.4M | $1.1M | $3.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $43.7M | $35.8M | $19.3M | $31.4M | $46.4M | $41.5M | $24.5M | $97.2M |
| SG&A Expense | $30.5M | $34.4M | $31.9M | $21.2M | $19.1M | $16.8M | $13.6M | $9.6M |
| Operating Income | $-37.3M | $-68.6M | $-47.5M | $-49.2M | $-62.7M | $-55.4M | $-36.8M | $-102.6M |
| Operating Margin | -104.3% | -12,400.7% | -1,684.5% | -1,784.4% | -2,386.1% | -2,264.6% | -3,443.3% | -3,289.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-36.3M | $-68.1M | $-83.7M | $-48.9M | $-62.6M | $-55.0M | $-35.7M | $-100.7M |
| Net Margin | -101.6% | -12,322.6% | -2,966.2% | -1,774.0% | -2,381.8% | -2,251.2% | -3,338.2% | -3,228.2% |
| EPS (Basic) | $-0.15 | $-0.28 | $3.02 | $-0.02 | $-0.15 | $-0.32 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.15 | $-0.28 | $3.02 | $-0.02 | $-0.15 | $-0.32 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 246.3M | 244.2M | 135.9M | 2.39B | 427.1M | 172.7M | — | — |
| Shares Outstanding (Diluted) | 246.3M | 244.2M | 135.9M | 2.39B | 427.1M | 172.7M | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |